Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

348 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults.
Allen DB, Backeljauw P, Bidlingmaier M, Biller BM, Boguszewski M, Burman P, Butler G, Chihara K, Christiansen J, Cianfarani S, Clayton P, Clemmons D, Cohen P, Darendeliler F, Deal C, Dunger D, Erfurth EM, Fuqua JS, Grimberg A, Haymond M, Higham C, Ho K, Hoffman AR, Hokken-Koelega A, Johannsson G, Juul A, Kopchick J, Lee P, Pollak M, Radovick S, Robison L, Rosenfeld R, Ross RJ, Savendahl L, Saenger P, Sorensen HT, Stochholm K, Strasburger C, Swerdlow A, Thorner M. Allen DB, et al. Among authors: bidlingmaier m. Eur J Endocrinol. 2016 Feb;174(2):P1-9. doi: 10.1530/EJE-15-0873. Epub 2015 Nov 12. Eur J Endocrinol. 2016. PMID: 26563978 Free PMC article.
Detection of doping with human growth hormone.
Wu Z, Bidlingmaier M, Dall R, Strasburger CJ. Wu Z, et al. Among authors: bidlingmaier m. Lancet. 1999 Mar 13;353(9156):895. doi: 10.1016/S0140-6736(99)00775-8. Lancet. 1999. PMID: 10093984 No abstract available.
Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.
Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ. Trainer PJ, et al. Among authors: bidlingmaier m. N Engl J Med. 2000 Apr 20;342(16):1171-7. doi: 10.1056/NEJM200004203421604. N Engl J Med. 2000. PMID: 10770982 Free article. Clinical Trial.
Test method: GH.
Bidlingmaier M, Wu Z, Strasburger CJ. Bidlingmaier M, et al. Baillieres Best Pract Res Clin Endocrinol Metab. 2000 Mar;14(1):99-109. doi: 10.1053/beem.2000.0057. Baillieres Best Pract Res Clin Endocrinol Metab. 2000. PMID: 10932814 Review.
Changes in non-22-kilodalton (kDa) isoforms of growth hormone (GH) after administration of 22-kDa recombinant human GH in trained adult males.
Wallace JD, Cuneo RC, Bidlingmaier M, Lundberg PA, Carlsson L, Boguszewski CL, Hay J, Boroujerdi M, Cittadini A, Dall R, Rosén T, Strasburger CJ. Wallace JD, et al. Among authors: bidlingmaier m. J Clin Endocrinol Metab. 2001 Apr;86(4):1731-7. doi: 10.1210/jcem.86.4.7379. J Clin Endocrinol Metab. 2001. PMID: 11297610 Clinical Trial.
Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-peg), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men.
Veldhuis JD, Bidlingmaier M, Anderson SM, Wu Z, Strasburger CJ. Veldhuis JD, et al. Among authors: bidlingmaier m. J Clin Endocrinol Metab. 2001 Jul;86(7):3304-10. doi: 10.1210/jcem.86.7.7656. J Clin Endocrinol Metab. 2001. PMID: 11443205 Clinical Trial.
348 results